FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2075877031> ?p ?o ?g. }

• W2075877031 endingPage "555" @default.
• W2075877031 startingPage "552" @default.
• W2075877031 abstract "Somatic TP53 mutations are highly prevalent in therapy-related acute myeloid leukaemia and myelodysplastic syndrome, which arise as complications of cytotoxic chemotherapy or radiotherapy; although it was believed that these TP53 mutations are directly induced by cytotoxic therapy, new data indicate that they predate cytotoxic therapy and that haematopoietic progenitors harbouring these pre-existing mutations may selectively expand after exposure to chemotherapy or radiotherapy. The clonal haematopoietic disorders known as therapy-related acute myeloid leukaemia (t-AML) and therapy-related myelodysplastic syndrome (t-MDS) typically develop 1 to 5 years after exposure to chemotherapy or radiotherapy. TP53 mutations are selectively enriched in t-AML/t-MDS, and were thought to be directly induced by cytotoxic therapy. Now Daniel Link and colleagues present genome sequencing data that suggest the TP53 mutations predate cytotoxic therapy. It appears that rare haematopoietic stem/progenitor cells in blood or bone marrow carry age-related TP53 mutations, and that these cells undergo clonal expansion only after selective pressure applied by chemotherapy. Therapy-related acute myeloid leukaemia (t-AML) and therapy-related myelodysplastic syndrome (t-MDS) are well-recognized complications of cytotoxic chemotherapy and/or radiotherapy1. There are several features that distinguish t-AML from de novo AML, including a higher incidence of TP53 mutations2,3, abnormalities of chromosomes 5 or 7, complex cytogenetics and a reduced response to chemotherapy4. However, it is not clear how prior exposure to cytotoxic therapy influences leukaemogenesis. In particular, the mechanism by which TP53 mutations are selectively enriched in t-AML/t-MDS is unknown. Here, by sequencing the genomes of 22 patients with t-AML, we show that the total number of somatic single-nucleotide variants and the percentage of chemotherapy-related transversions are similar in t-AML and de novo AML, indicating that previous chemotherapy does not induce genome-wide DNA damage. We identified four cases of t-AML/t-MDS in which the exact TP53 mutation found at diagnosis was also present at low frequencies (0.003–0.7%) in mobilized blood leukocytes or bone marrow 3–6 years before the development of t-AML/t-MDS, including two cases in which the relevant TP53 mutation was detected before any chemotherapy. Moreover, functional TP53 mutations were identified in small populations of peripheral blood cells of healthy chemotherapy-naive elderly individuals. Finally, in mouse bone marrow chimaeras containing both wild-type and Tp53+/− haematopoietic stem/progenitor cells (HSPCs), the Tp53+/− HSPCs preferentially expanded after exposure to chemotherapy. These data suggest that cytotoxic therapy does not directly induce TP53 mutations. Rather, they support a model in which rare HSPCs carrying age-related TP53 mutations are resistant to chemotherapy and expand preferentially after treatment. The early acquisition of TP53 mutations in the founding HSPC clone probably contributes to the frequent cytogenetic abnormalities and poor responses to chemotherapy that are typical of patients with t-AML/t-MDS." @default.
• W2075877031 created "2016-06-24" @default.
• W2075877031 creator A5003442518 @default.
• W2075877031 creator A5006673204 @default.
• W2075877031 creator A5014714324 @default.
• W2075877031 creator A5015109937 @default.
• W2075877031 creator A5018151522 @default.
• W2075877031 creator A5030586623 @default.
• W2075877031 creator A5031896350 @default.
• W2075877031 creator A5035432960 @default.
• W2075877031 creator A5037939444 @default.
• W2075877031 creator A5049284725 @default.
• W2075877031 creator A5052629830 @default.
• W2075877031 creator A5054642128 @default.
• W2075877031 creator A5056298434 @default.
• W2075877031 creator A5056864458 @default.
• W2075877031 creator A5056921013 @default.
• W2075877031 creator A5057569401 @default.
• W2075877031 creator A5061026009 @default.
• W2075877031 creator A5064410148 @default.
• W2075877031 creator A5065066309 @default.
• W2075877031 creator A5076598094 @default.
• W2075877031 creator A5081128399 @default.
• W2075877031 creator A5081851296 @default.
• W2075877031 creator A5082251778 @default.
• W2075877031 date "2014-12-08" @default.
• W2075877031 modified "2023-10-16" @default.
• W2075877031 title "Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia" @default.
• W2075877031 cites W1255676896 @default.
• W2075877031 cites W1851609974 @default.
• W2075877031 cites W1986076152 @default.
• W2075877031 cites W1994791499 @default.
• W2075877031 cites W2000738792 @default.
• W2075877031 cites W2012753533 @default.
• W2075877031 cites W2022495797 @default.
• W2075877031 cites W2023560061 @default.
• W2075877031 cites W2041596445 @default.
• W2075877031 cites W2042316019 @default.
• W2075877031 cites W2051972371 @default.
• W2075877031 cites W2058631780 @default.
• W2075877031 cites W2064543601 @default.
• W2075877031 cites W2065817684 @default.
• W2075877031 cites W2066218351 @default.
• W2075877031 cites W2066679661 @default.
• W2075877031 cites W2068371312 @default.
• W2075877031 cites W2072193332 @default.
• W2075877031 cites W2093144236 @default.
• W2075877031 cites W2097540657 @default.
• W2075877031 cites W2103441770 @default.
• W2075877031 cites W2108234281 @default.
• W2075877031 cites W2116052270 @default.
• W2075877031 cites W2117131162 @default.
• W2075877031 cites W2119180969 @default.
• W2075877031 cites W2129905922 @default.
• W2075877031 cites W2134061682 @default.
• W2075877031 cites W2143197030 @default.
• W2075877031 cites W2149278033 @default.
• W2075877031 cites W2151794156 @default.
• W2075877031 cites W2152241467 @default.
• W2075877031 cites W2154397429 @default.
• W2075877031 cites W2155943701 @default.
• W2075877031 cites W2157783208 @default.
• W2075877031 cites W2163067447 @default.
• W2075877031 cites W2168420558 @default.
• W2075877031 cites W2169313200 @default.
• W2075877031 cites W2170551349 @default.
• W2075877031 cites W4230096730 @default.
• W2075877031 doi "https://doi.org/10.1038/nature13968" @default.
• W2075877031 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4403236" @default.
• W2075877031 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25487151" @default.
• W2075877031 hasPublicationYear "2014" @default.
• W2075877031 type Work @default.
• W2075877031 sameAs 2075877031 @default.
• W2075877031 citedByCount "654" @default.
• W2075877031 countsByYear W20758770312014 @default.
• W2075877031 countsByYear W20758770312015 @default.
• W2075877031 countsByYear W20758770312016 @default.
• W2075877031 countsByYear W20758770312017 @default.
• W2075877031 countsByYear W20758770312018 @default.
• W2075877031 countsByYear W20758770312019 @default.
• W2075877031 countsByYear W20758770312020 @default.
• W2075877031 countsByYear W20758770312021 @default.
• W2075877031 countsByYear W20758770312022 @default.
• W2075877031 countsByYear W20758770312023 @default.
• W2075877031 crossrefType "journal-article" @default.
• W2075877031 hasAuthorship W2075877031A5003442518 @default.
• W2075877031 hasAuthorship W2075877031A5006673204 @default.
• W2075877031 hasAuthorship W2075877031A5014714324 @default.
• W2075877031 hasAuthorship W2075877031A5015109937 @default.
• W2075877031 hasAuthorship W2075877031A5018151522 @default.
• W2075877031 hasAuthorship W2075877031A5030586623 @default.
• W2075877031 hasAuthorship W2075877031A5031896350 @default.
• W2075877031 hasAuthorship W2075877031A5035432960 @default.
• W2075877031 hasAuthorship W2075877031A5037939444 @default.
• W2075877031 hasAuthorship W2075877031A5049284725 @default.
• W2075877031 hasAuthorship W2075877031A5052629830 @default.
• W2075877031 hasAuthorship W2075877031A5054642128 @default.
• W2075877031 hasAuthorship W2075877031A5056298434 @default.

• next